, Volume 8, Issue 1, pp 64-65
Date: 22 Dec 2011

Patient Evaluation and OA Study Design: OARSI/Biomarker Qualification

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Introduction

Qualification is defined as the “graded, ‘fit-for-purpose’ evidentiary process linking a biomarker with biology and clinical endpoints” [5]. As recently defined by the Federal Drug Administration (FDA), “qualification is a conclusion that within the stated context (manner and purpose) of use, the results of assessment with a drug development tool (DDT) can be relied upon to have a specific interpretation and application in drug development and regulatory decision making” [3].

Biomarkers of OA

However, currently there are no FDA-qualified osteoarthritis (OA) biomarkers. All OA biomarkers in current use are for research use only. There are two biomarkers, NTX1 and CTX1, used in osteoporosis research and clinical monitoring that are in fact in vitro diagnostics for osteoporosis. These, along with the advent, in 1979, of dual-energy photon absorptiometry as an FDA-approved method for quantifying bone mass of the spine, led to the rapid development of effective osteoporosis drugs